[1]鱼天英,任彦林△,李晓苗,等.地特胰岛素联合门冬胰岛素对1型糖尿病患儿糖脂指标、生存质量的影响研究*[J].陕西医学杂志,2020,49(12):1661-1664.[doi:DOI:10.3969/j.issn.1000-7377.2020.12.033]
　YU Tianying,REN Yanlin,LI Xiaomiao,et al.Effect of insulin detemir combined with insulin aspart on glucose and lipid indexes and quality of life in children with type 1 diabetes mellitus[J].,2020,49(12):1661-1664.[doi:DOI:10.3969/j.issn.1000-7377.2020.12.033]
点击复制

地特胰岛素联合门冬胰岛素对1型糖尿病患儿糖脂指标、生存质量的影响研究*
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年12期
页码:
1661-1664
栏目:
药物与临床
出版日期:
2020-12-05

文章信息/Info

Title:
Effect of insulin detemir combined with insulin aspart on glucose and lipid indexes and quality of life in children with type 1 diabetes mellitus
作者:
鱼天英1; 任彦林2△; 李晓苗1; 刘 霞1
1.陕西省榆林市中医医院内分泌科(榆林 719000); 2.陕西省榆林市中医医院儿科(榆林 719000)
Author(s):
YU Tianying; REN Yanlin; LI Xiaomiao; et al.
Department of Endocrinology,Yulin Hospital of Traditional Chinese Medicine,Shaanxi Province(Yulin 719000)
关键词:
1型糖尿病;  地特胰岛素;  门冬胰岛素;  糖脂指标;  氧化应激指标;  生存质量
Keywords:
Type 1 diabetes mellitus;  Insulin detemir;  Insulin aspart;  Glycolipid indicators;  Oxidative stress indicator;  Quality of life
分类号:
R587.1
DOI:
DOI:10.3969/j.issn.1000-7377.2020.12.033
文献标志码:
A
摘要:
目的:研究地特胰岛素联合门冬胰岛素对1型糖尿病(T1DM)患儿糖脂指标、生存质量的影响。方法:选取105例T1DM患儿为研究对象,采用随机数字法分为对照组(n=52)和观察组(n=53)。对照组和观察组分别给予诺和灵N联合生物合成人胰岛素、地特胰岛素联合门冬胰岛素进行治疗。比较两组血糖指标[空腹血糖(FBG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)]、脂代谢指标[高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)和总胆固醇(TC)]、氧化应激指标[丙二醛(MDA)、超氧化物歧化酶(SOD)和谷胱甘肽过氧化物酶(GSH-Px)]、生存质量评分及低血糖发生情况。结果:治疗后,观察组FBG、2hPG、HbA1c、TC、TG、LDL-C、MDA、SOD水平均低于对照组,GSH-Px、HDL-C水平高于对照组(P<0.05); 与对照组比较,观察组生存质量评分较高,低血糖发生率较低(P<0.05)。结论:地特胰岛素联合门冬胰岛素可改善T1DM患儿糖脂指标和氧化应激指标,提高生存质量,安全性较高。
Abstract:
Objective:To study the effect of insulin detemir combined with insulin aspart on glucose and lipid indexes and quality of life in children with type 1 diabetes mellitus(T1DM). Methods:A total of 105 T1DM children were enrolled as subjects. They were divided into observation group(53 cases)and control group(52 cases)by random number table method. The control group was treated with Nuovolin N combined with biosynthetic human insulin,while the observation group was treated with insulin detemir combined with insulin aspart. The blood glucose indicators(FBG,2hPG and HbA1c ),lipid metabolism indicators(HDL-C,LDL-C,TG and TC),oxidative stress indicators(MDA,SOD and GSH-Px),quality of life score and incidence of hypoglycemia were compared between the two groups.Results:After treatment,the levels of FBG,2hPG,HbA1c,TC,TG,LDL-C,SOD and MDA in observation group were lower than those in control group,while the levels of GSH-Px and HDL-C were higher than those in the control group(P<0.05). After treatment,the quality of life score in observation group was higher than that in control group(P<0.05). The incidence of hypoglycemia in observation group was lower than that in control group(P<0.05). Conclusion:Insulin detemir combined with insulin aspart can improve glucose and lipid indicators and oxidative stress indicators in children with T1DM,improve the quality of life,and have a higher safety.

参考文献/References:

[1] 罗 荔.降糖饮联合西药治疗儿童1型糖尿病44例[J].陕西中医,2016,37(10):1299-1300.
[2] 贺亚峰,郑 皓,杨 庚,等.甘精胰岛素联合瑞格列奈与双相门冬胰岛素治疗新诊断2型糖尿病的效果比较[J].贵州医药,2019,43(9):1412-1413.
[3] Lu JK,Pan QH,Pan HL,et al. Effects of insulin glargine and insulin aspart 30 on β-cell function and blood glucose level in patients with type 2 diabetes mellitus[J].Journal of Guangxi Medical University,2019,36(1):27-30.
[4] Zhao X,Zhang YY. Clinical evaluation of insulin glargine combined with insulin aspart in treatment of patients with type 2 diabetes[J].Drug Evaluation Study,2018,41(2):305-308.
[5] 李 玲.地特胰岛素与门冬胰岛素联合治疗妊娠糖尿病的安全性及有效性[J].糖尿病新世界,2019,22(21):57-58.
[6] 施 萍.1型儿童糖尿病的诊断与治疗[J].中国社区医师,2011,27(9):5.
[7] 李 佳,王旭艳,刘 超,等.胰岛素泵持续皮下注射胰岛素对1型糖尿病酮症酸中毒患儿机体代谢紊乱纠正效果研究[J].陕西医学杂志,2018,47(6):726-729.
[8] Zhu HF,Wang DP,Zhuang TW,et al. Efficacy and safety of insulin glargine combined with metformin in treatment of type 2 diabetes mellitus[J].Evaluation and Analysis of Drug Use in Chinese Hospitals,2018,18(11):1492-1494.
[9] 郑超君,徐锦龙,马卫成,等.沙格列汀联合门冬胰岛素30治疗老年Ⅱ型糖尿病患者的系统评价[J].循证医学,2019,19(4):229-236.
[10] 文 静,刘 毓,高爱民,等.地特胰岛素联合门冬胰岛素治疗儿童1型糖尿病的疗效观察[J].保健医学研究与实践,2018,15(3):55-57.
[11] 孟宪杰,李 莉,常绍菊,等.地特胰岛素联合复方丹参滴丸对2型糖尿病合并冠心病病人炎性因子水平、调控因子活性和胰岛素抵抗的影响[J].中西医结合心脑血管病杂志,2017,15(9):1093-1096.
[12] 陈伟铭,张选国,陈 菲.加味黄芪桂枝五物汤联合地特胰岛素治疗老年2型糖尿病周围神经病变疗效评价[J].山西医药杂志,2018,47(24):3005-3006.
[13] 刘 芳,沈凌花,陈 琼,等.地特胰岛素注射液联合短效胰岛素治疗学龄期儿童1型糖尿病疗效分析[J].儿科药学杂志,2018,24(6):7-9.
[14] 张灵芝,童颖薇.门冬胰岛素与甘精胰岛素联合治疗儿童1型糖尿病的疗效观察[J].中国妇幼健康研究,2017,28(S1):494-495.
[15] 陆锦昆,潘琼华,潘海林,等.甘精胰岛素与门冬胰岛素30对2型糖尿病患者胰岛β细胞功能及血糖稳定性的影响[J].广西医科大学学报,2019,36(1):33-36.
[16] 马齐芳.地特胰岛素与门冬胰岛素30联合二甲双胍治疗2型糖尿病疗效及安全性对比[J].中国药业,2018,27(22):65-67.
[17] 吴 颛.胰岛β细胞氧化应激反应及其在1型糖尿病中的作用[J].微生物学免疫学进展,2019,47(6):87-90.
[18] 尹 莉,张玉凤.初发1型糖尿病儿童甲状腺激素,氧化应激指标检测及临床意义[J].海南医学,2019,30(24):3162-3165.
[19] 金 菊.地特胰岛素联合门冬胰岛素皮下注射治疗2型糖尿病效果观察[J].黑龙江医药,2017,30(1):105-107.
[20] 陈红霞,徐 娜.双相门冬胰岛素30与地特胰岛素对口服降糖药失败的2型糖尿病患者的疗效及低血糖发生的影响[J].药物评价研究,2018,41(7):134-137.
[21] 陆玉莲,钱铁镛,陈一丁,等.口服降糖药分别联合不同胰岛素类似物治疗血糖控制不佳2型糖尿病的临床研究[J].中国全科医学,2018,21(23):20-24.
[22] 高 瑞,孔德博,吴护群,等.门冬胰岛素联合地特胰岛素对新诊断2型糖尿病患者血糖和胰岛β细胞功能的影响[J].药物评价研究,2019,42(11):2202-2205.
[23] 邓棋芳,周 瑞,王 霞,等.盐酸二甲双胍、生物合成人胰岛素联合门冬胰岛素治疗妊娠期糖尿病的疗效及妊娠结局比较[J].海南医学,2017,28(23):3816-3819.
[24] 张雪莲,崔 玲,罗 斌,等.门冬胰岛素30与预混人胰岛素治疗中国2型糖尿病患者的Meta分析[J].中国糖尿病杂志,2018,26(9):25-34.

备注/Memo

备注/Memo:
*陕西省社会发展科技攻关项目(201701328)
更新日期/Last Update: 2020-12-11